Market Chatter: FDA to Revamp Rare Disease Approval Process

10:22 AM EDT, 10/14/2026 (MT Newswires) -- The US Food and Drug Administration will review its approach to drug development and approvals for rare diseases under a new Rare Disease Framework Initiative, Bloomberg News reported Wednesday. The initiative, being announced Wednesday, aims to develop a system that increases patient input and provides companies with more regulatory clarity, according to the report. The US Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)